Loomis, Sayles & Company
AGN.PRA

Loomis, Sayles & Company’s Allergan plc AGN.PRA Stock Holding History

Loomis, Sayles & Company’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-16,338
Closed -$3.38M – 960
2017
Q4 		$3.38M Buy
16,338
+10,816
+196% +$6.98M 0.01% 538
2017
Q3 		$1.44M Buy
5,522
+349
+7% +$290K ﹤0.01% 555
2017
Q2 		$1.26M Sell
5,173
-208,432
-98% -$175M ﹤0.01% 555
2017
Q1 		$51M Sell
213,605
-45,979
-18% -$38.1M 0.13% 96
2016
Q4 		$69.8M Buy
+259,584
New +$196M 0.17% 76

Other funds holding AGN.PRA

PWS
Peloton Wealth Strategists Indianapolis, Indiana $247M AUM 13.57% 1-Year Est. Return

Loomis, Sayles & Company's AGN.PRA Position: Q1 2018 in Review

Loomis, Sayles & Company sold out of Allergan plc (AGN.PRA) in Q1 2018, closing a stake of 16,338 shares — an estimated $3.38M sold.

Loomis, Sayles & Company first reported a position in AGN.PRA in Q4 2016 and held it in 5 quarters. The position peaked at $69.8M in Q4 2016. 1 fund tracked by Wall St. Rank holds AGN.PRA as of Q1 2018.

  • Loomis, Sayles & Company reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
  • Loomis, Sayles & Company sold 16,338 Allergan plc shares in Q1 2018, an estimated $3.38M.
  • Loomis, Sayles & Company first reported a position in Allergan plc in Q4 2016 and held it in 5 quarters.
  • Loomis, Sayles & Company's Allergan plc position peaked at $69.8M in Q4 2016.
  • 1 fund tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on Loomis, Sayles & Company's 13F filing for Q1 2018, filed 11 May 2018.